Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04185558 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs

A NA study of Diabetic Foot and Chronic Ulcer, sponsored by RedDress.

Completed
Registry status
NA
Development phase
119
Enrollment target
16
Study locations

NCT04185558 is a NA study of Diabetic Foot and Chronic Ulcer that has completed, run by RedDress. The registered enrollment target is 119 participants, below the 10,337-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04185558, a NA study of Diabetic Foot and Chronic Ulcer, has completed, sponsored by RedDress.

COMPLETED
Registry status
NA
Development phase
119 participants
Enrollment target
16
Study locations

Study Summary

* The study is a multi-center, prospective, randomized, controlled, single blinded clinical study consisting of 150 subjects from up to 20 centers. * The subjects are randomized to receive 1 of 2 treatments, either with ActiGraft and standard of care (SOC) or with SOC alone. * The target ulcers are evaluated weekly by the investigator. The subject is treated once a week, to receive weekly applications of the ActiGraft + SOC or SOC until for up to 12 weeks or until the study ulcer has completely healed (i.e., 100% closure as assessed by the Investigator and blinded assessor and confirmed 2 weeks later at the healing confirmation visit (HCV). One additional visit per week is optional for both arms, for the purpose of changing only (1) the secondary dressing in the ActiGraft arm or (2) change the standard of care dressing in the control arm. * Immediately after the study ulcer is confirmed as completely healed, subjects will enter the 12-week Follow-up Phase. During the Follow-Up phase, subjects will be evaluated twice during the first month and then monthly for two additional visits every 4 weeks until the completion of the 12-week Follow-up Phase.

Interventions

  • DEVICE ActiGraft
  • DEVICE Standard of Care

Study Locations (16)

California

  • New Hope Podiatry Group Inc - Los Angeles
  • Greater Los Angeles VA - Los Angeles
  • Center for Clinical Research Inc - San Francisco
  • Olive View UCLA Education & Research Institute - Sylmar

Other

  • Wound Care South Africa - Germiston
  • Haute Care - Lyttelton
  • Eloquent Health & Wellness - Tyger Valley
  • Acinadem Altunizade - Istanbul

Florida

  • Eric J Lullove DPM PA - Coconut Creek
  • Future Health Research Clinic - Miami
  • Barry University Clinical Research - North Miami Beach

Alabama

  • Institute for Advanced Wound Care - Montgomery

Hawaii

  • Pacific Vascular Institute - Hilo

Massachusetts

  • Boston Medical Center - Boston

Nevada

  • Wahab Consulting and Research LLC - Las Vegas

Pennsylvania

  • Temple University - Philadelphia

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2019-12-20
Est. Completion 2024-04-01
Phase NA

Sponsor

RedDress

5 total trials

What the Registry Record Tells You About NCT04185558

The ClinicalTrials.gov registry entry for NCT04185558 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 10,337-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower). The listed sponsor is RedDress, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetic Foot appearing as the primary indexed condition, and to 2 interventions - of which ActiGraft is the first listed.

NCT04185558 reports 16 study locations spanning 8 distinct geographic areas - top geographies include California, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT04185558 about?

NCT04185558 is a clinical study titled "Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs". * The study is a multi-center, prospective, randomized, controlled, single blinded clinical study consisting of 150 subjects from up to 20 centers. * The subjects are randomized to receive 1 of 2 treatments, either with ActiGraft and standard of care (SOC) or with SOC alone. * The target ulcers are ...

What is the current status of trial NCT04185558?

This trial is currently completed. It is a NA study. The enrollment target is 119 participants. The study started on 2019-12-20. Estimated completion is 2024-04-01.

What conditions does trial NCT04185558 study?

This clinical trial studies the following conditions: Diabetic Foot, Chronic Ulcer.

What interventions are being tested in trial NCT04185558?

The interventions under investigation include: ActiGraft (DEVICE), Standard of Care (DEVICE).

Who is sponsoring clinical trial NCT04185558?

This trial is sponsored by RedDress, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04185558 being conducted?

This trial has 16 study locations across Alabama, California, Florida, Hawaii, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.